Status:
COMPLETED
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
Lead Sponsor:
Sanofi
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This is a randomized, placebo-controlled, four-part, Phase I, first in human (FIH) study to assess the tolerability and pharmacokinetics (PK) of ascending single and 14-day repeated oral doses of SAR4...
Eligibility Criteria
Inclusion
- Having given written informed consent prior to undertaking any study-related procedure.
Exclusion
- Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
August 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 23 2022
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT06106074
Start Date
August 10 2020
End Date
May 23 2022
Last Update
October 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Orleans Clinical Research Site Number : 8400001
Knoxville, Tennessee, United States, 37920